Precipio, Inc. announced another agreement with a new customer to bring HemeScreen™? technology into their laboratory. With each additional customer, Precipio continues to execute on its strategy, converting pipeline prospects to actual customers, and progressing towards breakeven.

The company incurs virtually no additional costs for the onboarding and maintenance of new customers, except for COVID-19 and associated production costs, which represent a relatively low cost of goods, generating a healthy margin for the Company. Because cost and business structure for the Products Division is largely fixed, each new customer has a substantial financial impact and contribution to the bottom line.